CN1927324A - Preparation method of traditional medicine preparation for treating women's menoxenia - Google Patents
Preparation method of traditional medicine preparation for treating women's menoxenia Download PDFInfo
- Publication number
- CN1927324A CN1927324A CN 200610053279 CN200610053279A CN1927324A CN 1927324 A CN1927324 A CN 1927324A CN 200610053279 CN200610053279 CN 200610053279 CN 200610053279 A CN200610053279 A CN 200610053279A CN 1927324 A CN1927324 A CN 1927324A
- Authority
- CN
- China
- Prior art keywords
- radix
- concentrated
- preparation
- surveys
- processed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 208000019255 Menstrual disease Diseases 0.000 title claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000008187 granular material Substances 0.000 claims abstract description 34
- 239000000843 powder Substances 0.000 claims abstract description 19
- 238000005325 percolation Methods 0.000 claims abstract description 15
- 238000009835 boiling Methods 0.000 claims abstract description 13
- 241000218176 Corydalis Species 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 10
- 239000000052 vinegar Substances 0.000 claims abstract description 10
- 235000021419 vinegar Nutrition 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920001353 Dextrin Polymers 0.000 claims abstract description 8
- 239000004375 Dextrin Substances 0.000 claims abstract description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 8
- 229930006000 Sucrose Natural products 0.000 claims abstract description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 8
- 230000006837 decompression Effects 0.000 claims abstract description 8
- 235000019425 dextrin Nutrition 0.000 claims abstract description 8
- 239000008101 lactose Substances 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 239000000796 flavoring agent Substances 0.000 claims description 17
- 235000019634 flavors Nutrition 0.000 claims description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 9
- 238000000703 high-speed centrifugation Methods 0.000 claims description 9
- 235000011477 liquorice Nutrition 0.000 claims description 9
- 241000628997 Flos Species 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 8
- 238000004064 recycling Methods 0.000 claims description 7
- 229960004793 sucrose Drugs 0.000 claims description 7
- 238000000889 atomisation Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 11
- 239000003390 Chinese drug Substances 0.000 abstract description 2
- 239000000706 filtrate Substances 0.000 abstract description 2
- 239000012141 concentrate Substances 0.000 abstract 3
- ACVGWSKVRYFWRP-UHFFFAOYSA-N Rutecarpine Chemical compound C1=CC=C2C(=O)N(CCC=3C4=CC=CC=C4NC=33)C3=NC2=C1 ACVGWSKVRYFWRP-UHFFFAOYSA-N 0.000 abstract 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000092665 Atractylodes macrocephala Species 0.000 abstract 1
- 235000008671 Calycanthus floridus Nutrition 0.000 abstract 1
- 235000008670 Calycanthus occidentalis Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241000207901 Cuscuta Species 0.000 abstract 1
- 244000150195 Cyperus longus Species 0.000 abstract 1
- 235000018109 Cyperus longus Nutrition 0.000 abstract 1
- 244000075634 Cyperus rotundus Species 0.000 abstract 1
- 241000735527 Eupatorium Species 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 244000148992 Lindera benzoin Species 0.000 abstract 1
- 235000004520 Lindera benzoin Nutrition 0.000 abstract 1
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 abstract 1
- BCPAKGGXGLGKIO-UHFFFAOYSA-N Pseudorutaecarpin Natural products C1=CC=C2C(=O)N(CCC3=C4C5=CC=CC=C5N3)C4=NC2=C1 BCPAKGGXGLGKIO-UHFFFAOYSA-N 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 235000005010 Scirpus paludosus Nutrition 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000005906 menstruation Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000004089 microcirculation Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
- 101800000989 Oxytocin Proteins 0.000 description 4
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 4
- 229960001723 oxytocin Drugs 0.000 description 4
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000713 mesentery Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000000264 venule Anatomy 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a preparation method of Chinese drugs pharmaceutics for the treatment of women's menstrual disorders. Steps are as follows: (1) recipe the aucklandiae, combined spicebush root, atractylodes macrocephala, corydalis processed with vinegar, Chinese angelica, nutgrass galingale rhizome, rutaecarpine prepared in licorice water, eupatorium and crush them into coarse powder, percolate with 70% ethanol solvent as dissolvent using the percolation method and collect the percolate, recover the alcohol with decompression, concentrate the percolate and the concentrated solution is reserved; (2) recipe Chuanxiong, prepared rehmannia root, paeoniae radix, safflower, salvia miltiorrhiza, caulis millettiae, cuscuta seed and add water to boil twice, put the physic liquor together, filt and concentrate, centrifugate on high-speed, add the concentrated solution above mentioned, continue to concentrate, reserve; (3) recipe the above mentioned extract by adding lactose, sucrose powder, dextrin, put them into the boiling granulating machine for further granulating and fiat into drug granules.
Description
Technical field
The present invention relates to the preparation method of Chinese medicine preparation, relate in particular to a kind of preparation method that is used for the treatment of the menoxenia Chinese medicine preparation.
Background technology
Menoxenia, dysmenorrhea are commonly encountered diseases, the frequently-occurring diseases in the gynecological, have brought inconvenience with worried in daily life, work for numerous women.Etiology and pathogenesis mainly is damaged by excess of seven emotions or diseases caused by exogenous pathogenic factor six climate exopathogens, or congenital deficiency of kidney-QI, and fecund is tired, and overstrain makes visceral-qi impaired, and the kidney function of liver and spleen is not normal, and qi and blood disorder causes and dashes wantonly two arteries and veins and damage and fall ill, and is many with qi depression to blood stasis.Patient's element depression of being worried more, gas is not declared and is reached, and blood is the stagnation of QI, and retardance is dashed and is appointed, and the menses operation is not smooth, and the sea of blood is spill-over on time, sends out to be menoxenia and dysmenorrhea.Qi depression to blood stasis causes menoxenia, and main clinical manifestation is: delay menstrual period, and amount is few, and color is dim red, or clot is arranged, or little petechia is arranged, and thready and hesitant pulse or string are puckery.Qi depression to blood stasis causes dysmenorrhea, and main clinical manifestation is: every menstruation is last, two days or menstrual period lower abdominal distention pain, tenderness, or companion's breast side of body, breast expand, or hypomenorrhea, or blockage of menstruation, dark menses has piece, and clot is discharged the back alleviation of pain, pain disappeared after menstruation, purplish tongue is dim or petechia is arranged, and stringy pulse or string are puckery.
The prescription that is used for the treatment of the menoxenia Chinese medicine preparation is a principal agent with Radix Angelicae Sinensis, Rhizoma Cyperi (system), benefiting blood and regulating blood circulation, the resolving depression of regulating the flow of vital energy; Be aided with Radix Salviae Miltiorrhizae, Caulis Spatholobi, Radix Paeoniae Rubra, Radix Rehmanniae Preparata, Herba Lycopi's nourishing blood and dissolving stasis; Assistant is with Rhizoma Chuanxiong, Rhizoma Corydalis (vinegar system), Flos Carthami, Radix Aucklandiae promoting flow of QI and blood, and the Rhizoma Atractylodis Macrocephalae, Semen Cuscutae are transferred spleen reinforcing kidney, the Radix Linderae, Fructus Evodiae (liquorice beverage system) dispelling cold by warming the meridian, promoting the circulation of QI to relieve pain.Have the effect of regulating menstruation and activating blood, promoting the circulation of QI to relieve pain, be used for menoxenia, diseases such as menalgia." regulating menstruation and activating blood sheet " in the 3rd 150 pages in oneself " Drug Standard of Ministry of Public Health of the Peoples Republic of China " Chinese traditional patent formulation preparation of we choosing side.
In former method for making, the Radix Aucklandiae, Rhizoma Chuanxiong, Rhizoma Corydalis and part Radix Angelicae Sinensis powder are broken into fine powder, standby; All the other flavour of a drug such as remaining Radix Angelicae Sinensis and Radix Rehmanniae Preparata decoct with water twice, and 3 hours for the first time, 2 hours for the second time, collecting decoction filtered, and filtrate is condensed into thick paste, adds above-mentioned fine powder and adjuvant, and mixing is made granule, drying, and tabletting, sugar coating, promptly.Promptly our clinically former be usefulness with the coated tablet, and the Radix Aucklandiae, Rhizoma Chuanxiong, Rhizoma Corydalis and part Radix Angelicae Sinensis medical material are starch in the side, and this operation of sugar coating man-hours requirement in actual production is long, supplies consumption is big, clothing layer weight increases too much (making sheet heavily increase by 50～100%), shortcomings such as the coated tablet that this preparation method obtains exists dose big (three times on the one, a time 5), disintegration rate is slow, bioavailability is low influence promoting the use of of this medicine.
Summary of the invention
The purpose of this invention is to provide a kind of preparation method that is used for the treatment of the menoxenia Chinese drugs agentia.
The step of preparation method that is used for the treatment of the menoxenia Chinese medicine preparation is as follows:
(1) get the Radix Aucklandiae 75～91g, the Radix Linderae 113～138g, the Rhizoma Atractylodis Macrocephalae 113～138g, Rhizoma Corydalis (processed with vinegar) 75～91g, Radix Angelicae Sinensis 225～275g, Rhizoma Cyperi (processed) 225～275g, liquorice beverage Fructus Evodiae (processed) 38～46g, Herba Lycopi 225～275g eight flavors are ground into coarse powder, adopting percolation is solvent with 65～75% ethanol, flood after 18～30 hours, carry out percolation, collect percolate 7500～8500ml, decompression recycling ethanol is concentrated into relative density 1.05～1.10, the concentrated solution of 62～68 ℃ of surveys, standby;
(2) get Rhizoma Chuanxiong 75～91g, Radix Rehmanniae Preparata 150～184g, Radix Paeoniae Rubra 150～184g, Flos Carthami 113～138g, Radix Salviae Miltiorrhizae 225～275g, Caulis Spatholobi 225～275g, Semen Cuscutae 300～366g seven flavors, decoct with water secondary, each 1.5 hours, medicinal liquid merged, filter, be concentrated into relative density 1.01～1.02,62～68 ℃ of surveys, high speed centrifugation, add above-mentioned concentrated solution, continue to be concentrated into relative density 1.15～1.20, the extractum of 62～68 ℃ of surveys, standby;
(3) get above-mentioned extractum and add lactose 324～396g, cane sugar powder 162～198g, dextrin 54～66g, put one-step palletizing in the boiling granulating device, make granule.
The step of preparation method that is used for the treatment of the menoxenia Chinese medicine preparation is as follows:
(1) get Radix Aucklandiae 83g, Radix Linderae 125g, Rhizoma Atractylodis Macrocephalae 125g, Rhizoma Corydalis (processed with vinegar) 83g, Radix Angelicae Sinensis 250g, Rhizoma Cyperi (processed) 250g, liquorice beverage Fructus Evodiae (processed) 42g, Herba Lycopi 250g eight flavors are ground into coarse powder, adopting percolation is solvent with 70% ethanol, flood after 24 hours, carry out percolation, collect percolate 8000ml, decompression recycling ethanol is concentrated into relative density 1.05～1.10, the concentrated solution of 65 ℃ of surveys, standby;
(2) get Rhizoma Chuanxiong 83g, Radix Rehmanniae Preparata 167g, Radix Paeoniae Rubra 167g, Flos Carthami 125g, Radix Salviae Miltiorrhizae 250g, Caulis Spatholobi 250g, Semen Cuscutae 333g seven flavors, decoct with water secondary, each 1.5 hours, medicinal liquid merged, filter, be concentrated into relative density 1.01～1.02,65 ℃ of surveys, high speed centrifugation, add above-mentioned concentrated solution, continue to be concentrated into relative density 1.15～1.20, the extractum of 65 ℃ of surveys, standby;
(3) above-mentioned extractum is added lactose 360g, cane sugar powder 180g, dextrin 60g, put one-step palletizing in the boiling granulating device, make granule.
Described high speed centrifugation speed is 10000～15000 rev/mins.Total gas source inlet pressure in the boiling granulating device is that 750～770Mpa, boiling negative pressure are that-22 * 100～-26 * 100Pa, jolting are that 25～35 seconds, jolting number of times are 5～7 times, inlet temperature off time: 65～75 ℃, outlet temperature are that 42～48 ℃, atomisation pressure are that 0.3～0.5Mpa, auxiliary air pressure: 0.04～0.06Mpa, air door pressure are 0.04～0.06Mpa.
Beneficial effect of the present invention: the present invention has the effect of regulating menstruation and activating blood, promoting the circulation of QI to relieve pain, is used for menoxenia, diseases such as menalgia.Under the prerequisite that does not influence drug effect, more former dosage form coated tablet has characteristics such as dose is little, onset is rapid; Process route is succinct, practical, is fit to big production.
The specific embodiment
Preparation method provided by the invention is then at the characteristics of each flavour of a drug in the prescription, and, factors considerations such as absorption fast, produce effects rapid, easy to carry, steady quality few from taking dose, adopt diverse ways to extract, and preferred its preparation technology parameter, make active ingredient farthest obtain keeping, thereby guarantee clinical efficacy.And former coated tablet made granule through form improvement, under the prerequisite that does not influence drug effect, reduce preparation dose (three times on the one, a time 1 bag), improve bioavailability, bring into play curative effect of medication quickly, also worked out the quality that practicable quality standard is controlled product.In addition; take that marumerization prepares granule in the boiling granulating device; comprise that with the granule preparation process of routine clear paste and mixed with excipients system soft material → soft material are by granule mechanism wet granular → wet grain drying → granulate → obtain granule to compare; the technological process of the method is more simple and practical, is fit to actual big production.
Embodiment 1
(1) get Radix Aucklandiae 83g, Radix Linderae 125g, Rhizoma Atractylodis Macrocephalae 125g, Rhizoma Corydalis (processed with vinegar) 83g, Radix Angelicae Sinensis 250g, Rhizoma Cyperi (processed) 250g, liquorice beverage Fructus Evodiae (processed) 42g, Herba Lycopi 250g eight flavors are ground into coarse powder, adopting percolation is solvent with 70% ethanol, flood after 24 hours, carry out percolation, collect percolate 8000ml, decompression recycling ethanol is concentrated into relative density 1.05～1.10, the concentrated solution of 65 ℃ of surveys, standby;
(2) get Rhizoma Chuanxiong 83g, Radix Rehmanniae Preparata 167g, Radix Paeoniae Rubra 167g, Flos Carthami 125g, Radix Salviae Miltiorrhizae 250g, Caulis Spatholobi 250g, Semen Cuscutae 333g seven flavors, decoct with water secondary, each 1.5 hours, medicinal liquid merged, filter, be concentrated into relative density 1.01～1.02,65 ℃ of surveys, high speed centrifugation, add above-mentioned concentrated solution, continue to be concentrated into relative density 1.15～1.20, the extractum of 65 ℃ of surveys, standby;
(3) get above-mentioned extractum and add lactose 360g, cane sugar powder 180g, dextrin 60g, put one-step palletizing in the boiling granulating device, make granule.
Embodiment 2
(1) get Radix Aucklandiae 75g, Radix Linderae 113g, Rhizoma Atractylodis Macrocephalae 113g, Rhizoma Corydalis (processed with vinegar) 75g, Radix Angelicae Sinensis 225g, Rhizoma Cyperi (processed) 22g, liquorice beverage Fructus Evodiae (processed) 38g, Herba Lycopi 225g eight flavors are ground into coarse powder, adopting percolation is solvent with 65% ethanol, flood after 18 hours, carry out percolation, collect percolate 7500ml, decompression recycling ethanol is concentrated into relative density 1.05～1.10, the concentrated solution of 62 ℃ of surveys, standby;
(2) get Rhizoma Chuanxiong 75g, Radix Rehmanniae Preparata 150g, Radix Paeoniae Rubra 150g, Flos Carthami 113g, Radix Salviae Miltiorrhizae 225g, Caulis Spatholobi 225g, Semen Cuscutae 300g seven flavors, decoct with water secondary, each 1.5 hours, medicinal liquid merged, filter, be concentrated into relative density 1.01～1.02,62 ℃ of surveys, high speed centrifugation, add above-mentioned concentrated solution, continue to be concentrated into relative density 1.15～1.20, the extractum of 62 ℃ of surveys, standby;
(3) get above-mentioned extractum and add lactose 324g, cane sugar powder 162g, dextrin 54g, put one-step palletizing in the boiling granulating device, make granule.
Embodiment 3
(1) get Radix Aucklandiae 91g, Radix Linderae 138g, Rhizoma Atractylodis Macrocephalae 138g, Rhizoma Corydalis (processed with vinegar) 91g, Radix Angelicae Sinensis 275g, Rhizoma Cyperi (processed) 275g, liquorice beverage Fructus Evodiae (processed) 46g, Herba Lycopi 275g eight flavors are ground into coarse powder, adopting percolation is solvent with 75% ethanol, flood after 30 hours, carry out percolation, collect percolate 8500ml, decompression recycling ethanol is concentrated into relative density 1.05～1.10, the concentrated solution of 68 ℃ of surveys, standby;
(2) get Rhizoma Chuanxiong 91g, Radix Rehmanniae Preparata 184g, Radix Paeoniae Rubra 184g, Flos Carthami 138g, Radix Salviae Miltiorrhizae 275g, Caulis Spatholobi 275g, Semen Cuscutae 366g seven flavors, decoct with water secondary, each 1.5 hours, medicinal liquid merged, filter, be concentrated into relative density 1.01～1.02,68 ℃ of surveys, high speed centrifugation, add above-mentioned concentrated solution, continue to be concentrated into relative density 1.15～1.20, the extractum of 68 ℃ of surveys, standby;
(3) get above-mentioned extractum and add lactose 396g, cane sugar powder 198g, dextrin 66g, put one-step palletizing in the boiling granulating device, make granule.
We are bright to provide a kind of preparation method that is used for the treatment of the menoxenia Chinese medicine preparation.For proving its therapeutic effect and safety, the granule that the method that the inventor uses to be provided in the foregoing description prepares has carried out toxicity and pharmacodynamics test, and has carried out the drug effect contrast with former dosage form coated tablet; Also the granule that the method that provides in use the foregoing description is prepared has been formulated quality standard, has investigated its stability; Result of study is as follows:
One, pharmacodynamics test
1, rheology test
Stasis syndrome disease SD hemorheology of rat result of the test is shown: granule can obviously reduce the low shear viscosity of acute blood stasis disease rat whole blood, packed cell volume, shortening erythrocyte electrophoretic time; Heavy dose of 4g (crude drug)/kg also has obvious reduction effect to high shear whole blood contrast viscosity.Show that it has the effect of invigorating blood circulation preferably.
2, microcirculation of mouse auricle is influenced
Mice Auricle microcirculation result of the test is shown: granule has obvious dilating effect to Mice Auricle venule, small artery caliber, can obviously increase Mice Auricle blood capillary openness (increase of blood capillary bar number), and obvious than the coated tablet effect, the granule Mice Auricle microcirculation that has clear improvement is described.
3, to the microcirculatory influence of rat mesentery
SD rat mesentery microcirculation result of the test shows: with the positive medicine of Anisodamine (654-2) sheet, by duodenal administration, granule can obviously improve the rat mesentery microcirculation.More obvious to expansion venule effect, venule, small artery inner blood flow velocity then there are not obvious influence.
4, mice analgesic activity (acetic acid twisting method) is studied
The acetic acid twisting method shows that to mice analgesic activity result of the test granule can obviously reduce the mouse writhing number of times due to the lumbar injection acetic acid, has illustrated analgesic activity preferably.
5, granule is studied mice analgesic activity (oxytocin writhing method)
The oxytocin writhing method shows mice analgesic activity result of the test: what granule can obviously reduce female mice pain due to the lumbar injection oxytocin turns round the body number of times, illustrates that it has analgesic activity preferably to dysmenorrhea.
6, granule is to the influence of isolated rat uterine contraction effect
Isolated rat uterine contraction result of the test is shown granule can obviously suppress the isolated uterine flesh contraction that oxytocin causes.
7, granule is to the influence of rat in the effect of body uterine contraction
The result shows that granule can obviously be suppressed at the contraction of body uterus muscle.
Two, acute toxicity test
Acute toxicity test in mice studies show that, irritates stomach (ig) the maximum granule that the present invention prepares of limiting the quantity of, and do not see in seven days that mice has abnormal response, and promptly single-dose is difficult to measure the oral LD of granule mice of the present invention
50The granule that the present invention prepares is neat peroral administration mtd test result show: mice is pressed (Cmax behind 103.2g crude drug/kg gastric infusion, maximum volume), all there is not tangible toxic reaction, no dead mouse, inspection is not seen any unusual yet in dissecting.The maximum tolerated dose that records the granule its mouse oral administration that the present invention prepares is 206.4g crude drug/kg/ day, is equivalent to 666 times of clinical adult oral dose on the one.
Three, long term toxicity test
SD rat long term toxicity test is the result show: the granule that the present invention prepares was with two continuous gastric infusions of dosage of 15g (crude drug)/kg, 7.5g (crude drug)/kg (being equivalent to intend 50,25 times with clinical dosage) 4 months, matched group is given the equal-volume normal saline, and the body weight, active situation, food-intake, appearance sign etc. of each group rat are all had no adverse effects; Secondary hematology, blood parameters testing result all show after two months and four months, index no significant differences such as the hemogram of administration group and matched group, total serum protein, albumin, creatinine, blood urea nitrogen, blood glucose, glutamate pyruvate transaminase, alkali phosphatase, cholesterol and total bilirubin; Hemoglobin then has certain rising, may be relevant with the effect of invigorating blood circulation of this medicine; Live and to cut open between inspection each main organs coefficient administration group of back and the matched group also no significant difference extremely; Pathological examination results has the slight interstitial pneumonia (it is relevant that medicinal liquid is strayed into lungs when irritating stomach) except that each group all has indivedual Mus lungs, and each main organs of organizing rat does not all have obvious pathological changes and takes place.Slowness toxicity is not seen in the convalescent period General observation in two weeks yet after the drug withdrawal; Two weeks were surveyed hemoglobin after convalescent periods, no significant difference between administration group as a result and the matched group.
Four, preparation technology and quality standard
In Study on Preparation, according to the heterogeneity of each flavour of a drug in the prescription, adopt diverse ways to extract, and preferred its preparation technology parameter, make active ingredient farthest obtain keeping, thereby guarantee clinical efficacy.
In the research of quality standard, prescription feature according to this medicine, respectively Radix Salviae Miltiorrhizae, Fructus Evodiae (liquorice beverage system), Rhizoma Corydalis (vinegar system), Radix Paeoniae Rubra have been carried out the TLC discriminating, with high-efficient liquid phase technique the effective ingredient peoniflorin in the Radix Paeoniae Rubra is carried out assay, and regulation this product contains paeoniflorin and must not be less than 2.0mg/g, controls the quality of product thus.
The sample stability test shows: three batches of granule samples that prepared by the present invention were placed 18 months down in room temperature, regulation by the quality standard draft checks that to its character, discriminating, inspection, assay, hygiology index the result shows respectively: said preparation is stable.
Claims (4)
1, a kind of preparation method that is used for the treatment of the menoxenia Chinese medicine preparation is characterized in that step is as follows:
(1) get the Radix Aucklandiae 75～91g, the Radix Linderae 113～138g, the Rhizoma Atractylodis Macrocephalae 113～138g, Rhizoma Corydalis (processed with vinegar) 75～91g, Radix Angelicae Sinensis 225～275g, Rhizoma Cyperi (processed) 225～275g, liquorice beverage Fructus Evodiae (processed) 38～46g, Herba Lycopi 225～275g eight flavors are ground into coarse powder, adopting percolation is solvent with 65～75% ethanol, flood after 18～30 hours, carry out percolation, collect percolate 7500～8500ml, decompression recycling ethanol is concentrated into relative density 1.05～1.10, the concentrated solution of 62～68 ℃ of surveys, standby;
(2) get Rhizoma Chuanxiong 75～91g, Radix Rehmanniae Preparata 150～184g, Radix Paeoniae Rubra 150～184g, Flos Carthami 113～138g, Radix Salviae Miltiorrhizae 225～275g, Caulis Spatholobi 225～275g, Semen Cuscutae 300～366g seven flavors, decoct with water secondary, each 1.5 hours, medicinal liquid merged, filter, be concentrated into relative density 1.01～1.02,62～68 ℃ of surveys, high speed centrifugation, add above-mentioned concentrated solution, continue to be concentrated into relative density 1.15～1.20, the extractum of 62～68 ℃ of surveys, standby;
(3) get above-mentioned extractum and add lactose 324～396g, cane sugar powder 162～198g, dextrin 54～66g, put one-step palletizing in the boiling granulating device, make granule.
2, a kind of preparation method that is used for the treatment of the menoxenia Chinese medicine preparation according to claim 1 is characterized in that step is as follows:
(1) get Radix Aucklandiae 83g, Radix Linderae 125g, Rhizoma Atractylodis Macrocephalae 125g, Rhizoma Corydalis (processed with vinegar) 83g, Radix Angelicae Sinensis 250g, Rhizoma Cyperi (processed) 250g, liquorice beverage Fructus Evodiae (processed) 42g, Herba Lycopi 250g eight flavors are ground into coarse powder, adopting percolation is solvent with 70% ethanol, flood after 24 hours, carry out percolation, collect percolate 8000ml, decompression recycling ethanol is concentrated into relative density 1.05～1.10, the concentrated solution of 65 ℃ of surveys, standby;
(2) get Rhizoma Chuanxiong 83g, Radix Rehmanniae Preparata 167g, Radix Paeoniae Rubra 167g, Flos Carthami 125g, Radix Salviae Miltiorrhizae 250g, Caulis Spatholobi 250g, Semen Cuscutae 333g seven flavors, decoct with water secondary, each 1.5 hours, medicinal liquid merged, filter, be concentrated into relative density 1.01～1.02,65 ℃ of surveys, high speed centrifugation, add above-mentioned concentrated solution, continue to be concentrated into relative density 1.15～1.20, the extractum of 65 ℃ of surveys, standby;
(3) get above-mentioned extractum and add lactose 360g, cane sugar powder 180g, dextrin 60g, put one-step palletizing in the boiling granulating device, make granule.
3, a kind of preparation method that is used for the treatment of the menoxenia Chinese medicine preparation according to claim 1 and 2 is characterized in that, described high speed centrifugation speed is 10000～15000 rev/mins.
4, a kind of preparation method that is used for the treatment of the menoxenia Chinese medicine preparation according to claim 1 and 2, it is characterized in that the total gas source inlet pressure in the described boiling granulating device one-step palletizing is that 750～770Mpa, boiling negative pressure are that-22 * 100～-26 * 100Pa, jolting are that 25～35 seconds, jolting number of times are 5～7 times, inlet temperature off time: 65～75 ℃, outlet temperature are that 42～48 ℃, atomisation pressure are that 0.3～0.5Mpa, auxiliary air pressure: 0.04～0.06Mpa, air door pressure are 0.04～0.06Mpa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100532795A CN100563630C (en) | 2006-09-06 | 2006-09-06 | The preparation method that is used for the treatment of the menoxenia Chinese medicine preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100532795A CN100563630C (en) | 2006-09-06 | 2006-09-06 | The preparation method that is used for the treatment of the menoxenia Chinese medicine preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1927324A true CN1927324A (en) | 2007-03-14 |
| CN100563630C CN100563630C (en) | 2009-12-02 |
Family
ID=37857555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100532795A Expired - Fee Related CN100563630C (en) | 2006-09-06 | 2006-09-06 | The preparation method that is used for the treatment of the menoxenia Chinese medicine preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100563630C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125283A (en) * | 2010-12-30 | 2011-07-20 | 陈慧婷 | Formula and preparation method of safflower and Chuanxiong drink for regulating female amenorrhea |
| CN101703656B (en) * | 2009-11-30 | 2012-03-21 | 贵阳新天药业股份有限公司 | Method for detecting quality of capsules for regulating menstruation and activating blood |
| CN102988667A (en) * | 2012-10-15 | 2013-03-27 | 李正梅 | Preparation method and application of tablet for regulating menstruation and activating blood |
| CN103386086A (en) * | 2013-07-21 | 2013-11-13 | 黄淑娟 | Traditional Chinese medicine composition for treating dysmenorrhea and preparation method thereof |
| CN104721355A (en) * | 2013-12-19 | 2015-06-24 | 王骁 | Foot bath traditional Chinese medicine and preparation method thereof |
-
2006
- 2006-09-06 CN CNB2006100532795A patent/CN100563630C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101703656B (en) * | 2009-11-30 | 2012-03-21 | 贵阳新天药业股份有限公司 | Method for detecting quality of capsules for regulating menstruation and activating blood |
| CN102125283A (en) * | 2010-12-30 | 2011-07-20 | 陈慧婷 | Formula and preparation method of safflower and Chuanxiong drink for regulating female amenorrhea |
| CN102988667A (en) * | 2012-10-15 | 2013-03-27 | 李正梅 | Preparation method and application of tablet for regulating menstruation and activating blood |
| CN103386086A (en) * | 2013-07-21 | 2013-11-13 | 黄淑娟 | Traditional Chinese medicine composition for treating dysmenorrhea and preparation method thereof |
| CN104721355A (en) * | 2013-12-19 | 2015-06-24 | 王骁 | Foot bath traditional Chinese medicine and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100563630C (en) | 2009-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857690A (en) | Gynecopathy treating preparation and its preparing process | |
| CN102772748B (en) | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof | |
| CN101007151A (en) | Traditional Chinese medicine and its preparation for treating chronic nephritis | |
| CN101214288B (en) | Traditional Chinese medicinal composition for treating hepatitis and its preparation | |
| CN100563630C (en) | The preparation method that is used for the treatment of the menoxenia Chinese medicine preparation | |
| CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
| CN103006989A (en) | Medical composition for treating diabetic nephropathy | |
| CN102847061A (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN101732585A (en) | Medicinal composition for treating migraine, preparation method and application thereof | |
| CN103349737B (en) | Traditional Chinese medicine composite for treating headache and preparation method of traditional Chinese medicine composite | |
| CN109876127B (en) | Blood-nourishing angelica sinensis capsule and preparation method thereof | |
| CN102772747A (en) | Traditional Chinese medicine preparation for treating heat-toxicity heart-disoperation type viral myocarditis | |
| CN108514627B (en) | A kind of traditional Chinese medicine composition for treating chronic urticaria | |
| CN101313989B (en) | Chinese medicinal composition for treating coronary disease, stenocardia | |
| CN105664102A (en) | Traditional Chinese medicine composition for improving immunity | |
| CN1047948C (en) | Oral natural drug composition for curing hysteromyoma | |
| CN105535070A (en) | Medicine composition for treating diabetes and preparation method and application thereof | |
| CN1931286A (en) | Chinese medicine composition for treating lung cancer caused pain | |
| CN1943718B (en) | A Chinese traditional medicinal composition and its preparation method | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN1709326A (en) | Method for preparing concentrated pill for treating mammary gland proliferation disease | |
| CN104491318A (en) | Traditional Chinese preparation used for treating asthma and preparation method of traditional Chinese preparation | |
| CN102772665B (en) | Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof | |
| CN100536899C (en) | Chinese medicine for treating and preventing early diabetes and nephropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091202 Termination date: 20190906 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |